Navigation Links
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Date:8/22/2007

s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4253

david.schull@russopartnersllc.com andreas.marathis@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...
(Date:12/4/2009)... (NYSE: AZN ) today announced that the ... SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive ... Disorder (MDD). SEROQUEL XR is the only medication in ... major depressive disorder as adjunctive therapy and acute depressive ...
(Date:12/3/2009)... , a leading primary research firm, today announced the launch ... that monitors and projects trends and market share in the ... captures actual patient usage for 87 different Sleep Apnea mask ... providers going back to January 2006. In the most ...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2German Alliance for Industrial Biotechnology Debuts in Montreal 12992 1German Alliance for Industrial Biotechnology Debuts in Montreal 12992 2Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 1Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 2Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 3Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 4Dynamic molecular mechanism to keep brain activity stable 51464 1
... SEATTLE, Aug. 22 Vical Incorporated (Nasdaq:,VICL) announced ... vaccine Phase 2a,clinical trials, using a plasmid DNA ... and manufactured by Vical, reinforced previously,reported Phase 1 ... was safe and well-tolerated, and was effective in ...
... Trial Examines Single, Higher, More Concentrated Dose of ... ... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced enrollment of the ... with,Mini-dose Alfimeprase-3) trial evaluating lead product candidate,alfimeprase, for the treatment of ...
Other Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 2Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 4
(Date:12/5/2009)... Youngest Babies, This Type of Blood Cancer Is Most ... 5 Pediatric oncologists have identified specific genes, dubbed ... an often-fatal form of leukemia in infants. By more ... predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 ... their 40th birthday without ever tying the knot, since research ... married folks. And, um, isn,t there something wrong with those ... A new study looking at psychological measures shows that never-married ...
(Date:12/5/2009)... by the National Association of Certified Professional Midwives ... for Midwifery (CfM), International Center for Traditional Childbearing ... the Midwifery Education Accreditation Council (MEAC). To ... Campaign to secure federal recognition of CPMs language ...
(Date:12/4/2009)... Care Investment Trust Inc. (NYSE: CRE ... Directors has declared a dividend of $0.17 per share of common ... common shareholders of record on December 14, 2009. ... Inc. is a real estate investment and finance company investing in ...
(Date:12/4/2009)... World Assurance,Company Holdings, Ltd (NYSE: AWH ) ... and Jack Sennott, Executive Vice,President and Chief Corporate Strategy ... Financial Services Conference being held at the Goldman,Sachs Conference ... 2009. ,, About Allied World ...
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... to recent rises in caesarean section rates, according to ... University. , The findings come from an analysis of ... team under Professor Gordon Smith, at the University,s Department ... more than 500,000 entries collected by the Scottish Morbidity ...
... depression, drug abuse, study says , , WEDNESDAY, July 2 ... in "sacred mushrooms" can last more than a year, ... investigations may lead to new ways to help people ... , In a previous study, the researchers gave psilocybin ...
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... is scheduled to present at the,Collins Stewart Growth ... Oriental Hotel in New York City., SuperGen,s ...
... CLARA, Calif., July 2 Align Technology,Inc. (Nasdaq: ... proprietary method of,straightening teeth without wires and brackets, ... 2008 financial results on Tuesday, July,29, 2008, after ... released,over PR Newswire and First Call and will ...
... 2 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX:,CUR), a life ... laboratory services, announced today that Dr. Timothy,J. Holzer, ... Dr. Scott,Waldman, from Thomas Jefferson University, were speakers ... session at the Eastern Cooperative Oncology,Group (ECOG), one ...
... Toronto Stock Exchange Symbol: CYT, MONTREAL, ... CYT), the global leader in cryotherapy products ... of Frank Vandeputte as Vice,President, Europe. Based ... Netherlands, Mr. Vandeputte will be responsible for ...
Other Medicine News:Health News:Major rise in Caesarean sections linked to impaired womb function with age 2Health News:Hallucinogen Gives Lasting Spiritual Boost 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:Align Technology to Announce Second Quarter Fiscal 2008 Results on July 29 2Health News:DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group 2Health News:DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group 3Health News:CryoCath Appoints Vice President, Europe 2
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... 2 fume containment system ... benchtop equipment. Even large ... inside the Hyperclean 2. ... system unit comes complete with ...
Medicine Products: